The DOI matches its Crossref record; 279 of the 279 references it cites were found in a registry or an index; 18 of the 48 sources its claims cite were checked for support.
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.
Open accessAbstract
Clinical practice guidelines summarising diagnosis, risk stratification, and management of PBC including ursodeoxycholic acid, obeticholic acid, and off-label therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
18 of 48 cited sources checked · 7 supported · 0 flagged · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“Serum bilirubin has been recognised since the 1970s as a major predictor of poor outcome in PBC [72,7].”
What the sources say
- Supportedcites [72] 72. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979;20:137-140. source
The 1979 paper’s Abstract (p. 137) identifies serum bilirubin as a predictor of prognosis in primary biliary cirrhosis. Its Presentation section reports that higher successive bilirubin levels were associated with shorter predicted survival, supporting the claim about poor outcome. (LLM, conf=0.93)
- Supportedcites [7] 7. Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014;147:1338-1349. source
The introduction (p. 2) calls serum bilirubin a well-established independent predictor of prognosis in PBC. Its cited references (p. 11) include a 1979 study titled “Serum bilirubin: a prognostic factor in primary biliary cirrhosis,” supporting the 1970s timeframe. (LLM, conf=0.91)
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Male sex is associated with later diagnosis, more advanced disease at presentation, poorer biochemical response to UDCA therapy, and higher risk of developing hepatocellular carcinoma (HCC) [6,8,65].”
What the sources say
- Partly supportedcites [6] 6. Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic Acid. Gastroenterology 2013;144:560-569. sourceExperimental — accuracy not yet measured
The Results and Discussion (page not provided) report that men with PBC presented at an older age, had signs suggesting more advanced disease and delayed diagnosis, and were less likely to meet UDCA response criteria. The passages found do not address whether men have a higher risk of developing HCC, so this source does not support that part of the sentence. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [8] 8. Trivedi PJ, Lammers WJ, van Buuren HR, Pares A, Floreani A, Janssen HL, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut 2016;65:321-329. source
- Not checked — no full text of the sourcecites [65] 65. Cheung A, Lammers WJ, Hirschfield GM, Invernizzi P, Mason A, Ponsioen CY, et al. Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis. J Hepatol 2015;62: S798-S799. source
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Patients who present at a younger age (\45 years) are often symptomatic and less likely to respond well to standard treatment with UDCA [6].”
What the sources say
- Supportedcites [6] 6. Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic Acid. Gastroenterology 2013;144:560-569. source
The Results and Discussion (page not available in our copy) report that patients presenting at younger ages were more likely to have fatigue and pruritus and less likely to respond to UDCA. The paper specifically identifies age 45 as a response threshold for women; the age-related response effect was weaker in men. (LLM, conf=0.88)
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The disease is chronic and often progressive, resulting in end-stage liver disease and its associated complications [6][7][8].”
What the sources say
- Partly supportedcites [6] 6. Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic Acid. Gastroenterology 2013;144:560-569. sourceExperimental — accuracy not yet measured
The Additional information section defines PBC-related failure to include liver transplantation or death from liver failure, supporting the possibility of severe outcomes. But the Discussion describes a potentially aggressive course particularly in younger patients, while characterizing the typical patient's course as relatively benign; it does not establish that PBC is often progressive to end-stage disease. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [7] 7. Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014;147:1338-1349. source
The introductory passage (p. 1) describes PBC as a chronic, slowly progressive disease that typically progresses to cirrhosis, which may lead to complications from liver failure. This supports the cited sentence’s description of progression to end-stage liver disease and associated complications. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [8] 8. Trivedi PJ, Lammers WJ, van Buuren HR, Pares A, Floreani A, Janssen HL, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut 2016;65:321-329. source
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“PBC recurrence has been reported in 20% of patients on average [253,258] but the rate of histological recurrence is likely higher [259].”
What the sources say
- Partly supportedcites [253] 253. Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol 2014;60:210-223. sourceExperimental — accuracy not yet measured
In the section on recurrence after liver transplantation (page unavailable), the paper reports recurrent PBC prevalence of 0–35% and 10-year incidence of 21–37%, but does not give a 20% average. It says recurrence can occur with normal liver tests and that biopsy practices affect reported rates, supporting the possibility of missed histological recurrence without quantifying how much higher its rate is. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [258] 258. Silveira MG, Talwalkar JA, Lindor KD, Wiesner RH. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant 2010;10:720-726. source
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Treatment with OCA is associated with a dose dependent exacerbation in pruritus, leading to treatment discontinuation in 4-10% of patients [130,131].”
What the sources say
- Partly supportedcites [130] 130. Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015;148:751-761. sourceExperimental — accuracy not yet measured
The Discussion describes pruritus as clearly OCA dose-related, and Study Patients reports that pruritus was the principal reason for discontinuation (10%). The cited 4–10% range is not established by these passages: Adverse Events reports 13% discontinuation due to pruritus in the open-label extension. Page numbers were not available in our copy. (LLM, conf=0.88)
- Supportedcites [131] 131. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016;375:631-643. source
The Safety and Side Effects section reports more pruritus in the 5–10 mg and 10 mg groups than in the placebo group, with the highest incidence at 10 mg. It also reports that 8 of 217 patients (4%) withdrew because of pruritus overall, while 7 patients (10%) in the 10 mg group discontinued treatment for that reason. The 5–10 mg group's discontinuation rate was lower, at 1%. (LLM, conf=0.88)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“PBC-specific ANA (antibodies against gp210 and sp100 antigens) are more frequently observed in patients with severe PBC and their presence may also be predictive of an unfavourable course, irrespective of serum bilirubin [75][76][77]63,78].”
What the sources say
- Not checked — no full text of the sourcecites [75] 75. Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003;98:431-437. source
- Partly supportedcites [76] 76. Rigopoulou EI, Davies ET, Pares A, Zachou K, Liaskos C, Bogdanos DP, et al. Prevalence and clinical significance of isotype specific antinuclear antibod- ies in primary biliary cirrhosis. Gut 2005;54:528-532. sourceExperimental — accuracy not yet measured
The Results and Discussion (page not available in our copy) associate PBC-specific ANA with more severe disease and worse outcomes, particularly for the multiple-nuclear-dot pattern. The study tested immunofluorescence patterns rather than separately establishing these findings for anti-gp210 and anti-sp100, and it does not show that the outcome association is independent of serum bilirubin. (LLM, conf=0.88)
- Partly supportedcites [77] 77. Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006;43:1135-1144. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) identifies gp210 and Sp100 as PBC-specific ANA targets and says PBC-specific ANA correlate with disease severity in cross-sectional studies. The Results (page unavailable) link anti-NPC antibodies, including anti-gp210, to poorer outcomes, but do not establish that anti-Sp100 predicts outcome. Anti-NPC added independent prognostic information only in patients with baseline bilirubin below 1 mg/dL, so the claim is too broad about prediction irrespective of bilirubin. (LLM, conf=0.88)
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Treatment failure must be defined on validated surrogate endpoints to account for the slow progression of disease, i.e. endpoints that have significant reproducible prognostic performance in different cohorts of patients [100].”
What the sources say
- Partly supportedcites [100] 100. Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 2010;52:349-359. sourceExperimental — accuracy not yet measured
The Endpoints of Clinical Trials in PBC section says slow progression makes death or transplantation impractical trial endpoints, and the Biochemical Markers section recommends biochemical markers as primary endpoints. But the paper does not say treatment failure must be defined by validated surrogates with reproducible prognostic performance across different cohorts; it allows several ways to assess response. Page numbers were not available in our copy. (LLM, conf=0.85)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“continuous scoring systems incorporating both measures of treatment response and parameters of disease severity [106,107].Thus, both the GLOBE score and the UK-PBC score have shown better performance for the prediction of death or liver transplantation than the Paris-I criteria, which have the best performance among binary models.”
What the sources say
- Partly supportedcites [106] 106. Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 2015;149:1804-1812. sourceExperimental — accuracy not yet measured
The Performance of the GLOBE Score Compared With Other Criteria section says GLOBE discriminated outcomes better than the earlier criteria; Table 3 reports higher C-statistics for GLOBE than Paris-1 and the other binary criteria. The paper also describes Paris-1 as generally having the best predictability among those criteria. It does not evaluate the UK-PBC score, so it cannot support that score’s claimed superiority to Paris-1; its mention of the UK-PBC consortium is not a comparison of scores. (LLM, conf=0.88)
- Partly supportedcites [107] 107. Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, et al. The UK- PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis. Hepatol- ogy 2016;63:930-950. sourceExperimental — accuracy not yet measured
The Validation of the PBC Risk Score section reports higher AUCs for UK-PBC than for Paris I, and Paris I has the highest AUCs among the four binary models compared. The paper does not report a GLOBE-score comparison, so it does not support that part of the claim. (LLM, conf=0.88)
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The enhanced liver fibrosis (ELF) score, which is computed from the simultaneous measurements of serum concentrations of hyaluronic acid, procollagen III peptide and tissue inhibitor of metalloproteinase 1, have shown similar predictive capacity [74].”
What the sources say
- Supportedcites [74] 74. Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008;48:1549-1557. source
The Methods identify hyaluronic acid, procollagen type III N-terminal propeptide, and TIMP-1 as components of the ELF assay. The Results report no statistically significant difference between ELF and histological staging in predicting clinical outcomes in patients with primary biliary cirrhosis, supporting similar predictive capacity in that comparison. (LLM, conf=0.90)
- Supported
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A diagnosis of primary biliary cholangitis is made if patients meet at least two of the following criteria: have biochemical evidence of chronic cholestasis, positive anti-mitochondrial antibodies in sera, and histological features compatible with primary biliary cholangitis.[3][4][5]”
From Primary biliary cholangitis. (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the treatment response to ursodeoxycholic acid was incomplete in about 20-40% of patients with primary biliary cholangitis after 1 year, as judged by various biochemical criteria, either binary or continuously.3”
From Primary biliary cholangitis. (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Clinically, primary biliary cholangitis is characterised by persistent elevation of cholestatic liver enzymes, including alkaline phosphatase and gammaglutamyl transpeptidase (GGT), and detection of antimitochondrial antibodies or primary biliary cholangitis-specific anti-nuclear antibodies (anti-sp100 or anti-gp210).[3][4][5]”
From Primary biliary cholangitis. (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Non-invasive liver stiffness measurement (LSM) has proven useful as an alternative to invasive liver biopsy for the evaluation of liver fibrosis, and LSM using transient elastography is recommended at the time of diagnosis.3,4,55”
From Primary biliary cholangitis. (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Clinical practice guidelines from the European Association for the Study of the Liver, the American Association for the Study of Liver Diseases (AASLD), and the Asian-Pacific Association for the Study of the Liver recommend ursodeoxycholic acid treatment (13-15 mg/kg per day) for all patients with primary biliary cholangitis and elevated cholestatic enzymes.[3][4][5]”
From Primary biliary cholangitis. (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Ursodeoxycholic acid is standard-of-care treatment for primary biliary cholangitis.”
From Primary biliary cholangitis. (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“For treatment, clinical indices have been developed to establish ursodeoxycholic acid treatment response at 1-2 years by biochemical tests, either binary or continuously.3”
From Primary biliary cholangitis. (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, the liver stiffness measurement (LSM) in stratifying the risk for progression has been confirmed.3,4,55”
From Primary biliary cholangitis. (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Ursodeoxycholic acid, a hydrophilic bile acid with choleretic and liver-protective properties, is currently the standard firstline therapy for primary biliary cholangitis.2,3”
From A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis (2018) · cites this paper as [2]
In the citing paper
“For sertraline as fourth-line treatment, no sufficient data for sclerosing cholangitis-associated itch exist.20,51”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [51]
In the citing paper
“Rifampicin was so far regarded as the most effective evidence-based treatment of cholestasis-associated pruritus, but it may induce drug-induced hepatitis after 4-12 weeks in up to 12% of cholestatic patients while the first 2 weeks are regarded as safe.20,51”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [51]
In the citing paper
“The evidence for the antipruritic effectiveness of the non-absorbable anion exchange resin cholestyramine in sclerosing cholangitis is limited when compared to PBC, 20,51 and that of the more potent anion exchange resin colesevelam is non-existent.217”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [51]
In the citing paper
“Abdominal discomfort | 20,51”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [51]
In the citing paper
“| No evidence for PSC | Sertraline (50-75 mg/d) | | 20,51 |”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [51]
In the citing paper
“| No evidence for PSC | Anion exchange resins (cholestyramine [4 g once to four | Abdominal discomfort | 20,51 |”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [51]
In the citing paper
“| 2 nd line | Rifampicin (150-300 mg/d) | Hepatitis | 20,51 |”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [51]
In the citing paper
“| 3 rd line | Naltrexone (12.5-50 mg/d) | Opioid withdrawal syndrome | 20,51 |”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [51]
In the citing paper
“In PBC, UDCA is used as first-line treatment,2 66 67 but 30%–50% of patients respond insufficiently (based on biochemical criteria)”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [66]
In the citing paper
“Current guideline-recommended medical treatment options for pruritus of cholestasis include the anion exchange resin cholestyramine, the pregnane X receptor (PXR) agonist rifampicin, the opioid antagonist naltrexone, and the selective serotonin reuptake inhibitor sertraline.4,7 Efficacy or tolerability of these drugs, or both, are limited.8,9”
From Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial (2021) · cites this paper as [4]
In the citing paper
“Studies investigating the association between bone diseases and chronic liver disease have mainly focused on cholestatic liver diseases [20].”
From Bone diseases in patients with chronic liver disease (2019) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Transplant-assessment bilirubin threshold has conflicting units
MinorThe recommendation pairs a bilirubin threshold of 50 mmol/L with 3 mg/dl, while the transplantation discussion pairs a threshold of 50-85 lmol/L with 3-5 mg/dl. The two passages give incompatible units for the same approximate threshold.
“persistent elevated bilirubin values [50 mmol/L or 3 mg/dl]”
“bilirubin values are rising progressively above 50-85 lmol/L (3-5 mg/dl)”
LDL is described as both elevated and not elevated
MinorThe hyperlipidaemia section reports elevated LDL in early disease and says it may rise further, but later states that LDL cholesterol is not elevated.
“In early disease, elevated very low density lipoprotein (VLDL) and LDL concentrations are reported, as well as significantly elevated HDL values.As disease progresses, LDL may increase further”
“It is clinically significant that HDL cholesterol is elevated whilst LDL cholesterol is not”
Citations
Cites
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Expanding consensus in portal hypertension
de Franchis, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.022 · Cited by 3,078
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
Simplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
Self-citation(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Diagnosis and management of autoimmune hepatitis
Manns, M. P., Czaja, A. J., Gorham, J. D., Krawitt, E. L., Mieli-Vergani, G., Vergani, D., & Vierling, J. M. (2010) · Hepatology · doi:10.1002/hep.23584 · Cited by 1,442
EASL Clinical Practice Guidelines: autoimmune hepatitis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.030 · Cited by 1,245
Schwab, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,241
Flagged first, then by citations
Research works printed but not linked: 1
- Corpechot, 2016, Relationships between biochemical response to UDCA and progression of liver stiffness as determined by Fibroscan in patients with PBC, Hepatology, 64, 194A
Cited by
Sorted by citations
Items 101–200 of 1,481
Sun, C., Xiao, X., Li, Y., Li, S., Wang, Q., Jiang, P., Lian, M., Li, Y., Wei, Y., Zhang, J., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.01.005 · Cited by 67
Bellan, M., Andréoli, L., Mele, C., Sainaghi, P. P., Rigamonti, C., Piantoni, S., Benedittis, C. D., Aimaretti, G., Pirisi, M., & Marzullo, P. (2020) · Nutrients · doi:10.3390/nu12030789 · Cited by 66
“presents with non-suppurative granulomas [232,233], and primary sclerosing cholangitis (PSC), affecting mainly young men with both small and large bile ducts involvement [234].”
BackgroundGerussi, A., Bernasconi, D. P., O’Donnell, S. E., Lammers, W. J., van Buuren, H., Hirschfield, G. M., Janssen, H. L. A., Corpechot, C., Reig, A., Parés, A. R., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.006 · Cited by 62
Self-citationTerziroli Beretta-Piccoli, B., Mieli-Vergani, G., & Vergani, D. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.004 · Cited by 61
John, B. V., Aitcheson, G. A., Schwartz, K. B., Khakoo, N. S., Dahman, B. A., Deng, Y., Goldberg, D. S., Martin, P. B., Taddei, T. H., Levy, C., et al. (2021) · Hepatology · doi:10.1002/hep.31776 · Cited by 63
NLRP3 inflammasome in hepatic diseases: A pharmacological target
Ramos‐Tovar, E., & Muriel, P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115861 · Cited by 66
Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists
Webb, G. J., Rana, A. A., Hodson, J. A., Akhtar, M. Z., Ferguson, J., Neuberger, J., Vierling, J. M., & Hirschfield, G. M. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.09.062 · Cited by 61
Self-citationLi, M., Wang, Q., Li, Y., Cao, S., Zhang, Y., Wang, Z., Liu, G., Li, J., & Gu, B. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107539 · Cited by 61
Kouroumalis, E., Voumvouraki, A., Augoustaki, A., & Samonakis, D. N. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i1.6 · Cited by 66
Hepatitis D diagnostics:Utilization and testing in the United States
Safaie, P., Razeghi, S., Rouster, S. D., et al. (2018) · Virus Research · doi:10.1016/j.virusres.2018.03.013 · Cited by 61
NUDT1 promotes the accumulation and longevity of CD103+ TRM cells in primary biliary cholangitis
Huang, B., Lyu, Z., Qian, Q., Chen, Y., Zhang, J., Li, B., Li, Y., Liang, J., Liu, Q., Li, Y., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.014 · Cited by 60
“24 In the present study, we found an apparent link between baseline CD103 + T RM cell numbers and response to UDCA in PBC.”
InfluentialMarschall, H., Henriksson, I., Lindberg, S., Söderdahl, F., Thuresson, M., Wåhlin, S., & Ludvigsson, J. F. (2019) · Scientific Reports · doi:10.1038/s41598-019-47890-2 · Cited by 61
Lemoinne, S., & Friedman, S. L. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.09.006 · Cited by 64
The pathogenesis, models and therapeutic advances of primary biliary cholangitis
Li, H., Guan, Y., Han, C., Zhang, Y., Liu, Q., Wei, W., & Ma, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111754 · Cited by 59
Andrade, L. E. C., Damoiseaux, J. G. M. C., Vergani, D., & Fritzler, M. J. (2022) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2022.100145 · Cited by 64
Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis
Colapietro, F., Maisonneuve, P., Lytvyak, E., Beuers, U. H., Verdonk, R. C., van der Meer, A. J., van Hoek, B., Kuiken, S. D., Brouwer, J. T., Muratori, P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.09.010 · Cited by 60
Self-citationNew scoring classification for primary biliary cholangitis–autoimmune hepatitis overlap syndrome
Zhang, W., De, D., Mohammed, K. A., Munigala, S., Chen, G., Lai, J., & Bacon, B. R. (2018) · Hepatology Communications · doi:10.1002/hep4.1148 · Cited by 59
Park, J. W., Kim, J. H., Kim, S. E., Jung, J. H., Jang, M. K., Park, S. H., Lee, M. S., Kim, H. S., Suk, K. T., & Kim, D. J. (2022) · Biomedicines · doi:10.3390/biomedicines10061288 · Cited by 60
Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?
Rodrigues, P. M., Perugorria, M. J., Santos‐Laso, Á., Bujanda, L., Beuers, U. H., & Bañales, J. M. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.08.020 · Cited by 58
Self-citationReal‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
Roberts, S. B., Ismail, M., Kanagalingam, G., Mason, A. L., Swain, M. G., Vincent, C., Yoshida, E. M., Tsien, C., Flemming, J. A., Janssen, H. L. A., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1518 · Cited by 58
Self-citationFibrotic Events in the Progression of Cholestatic Liver Disease
Wu, H., Chen, C., Ziani, S., Nelson, L. J., Avila, M. A., Nevzorova, Y. A., & Cubero, F. J. (2021) · Cells · doi:10.3390/cells10051107 · Cited by 62
Unique DUOX2+ACE2+ small cholangiocytes are pathogenic targets for primary biliary cholangitis
Li, X., Li, Y., Xiao, J., Wang, H., Guo, Y., Mao, X., Shi, P., Hou, Y., Zhang, X., Zhao, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-34606-w · Cited by 58
Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis
Dalekos, G. (2018) · Annals of Gastroenterology · doi:10.20524/aog.2018.0330 · Cited by 61
The intestinal and biliary microbiome in autoimmune liver disease—current evidence and concepts
Liwinski, T., Heinemann, M., & Schramm, C. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00936-6 · Cited by 60
“Several criteria for treatment response, including liver biochemical values, have been suggested [19, 21].”
BackgroundSelf-citationVitamin D–VDR Novel Anti-Inflammatory Molecules—New Insights into Their Effects on Liver Diseases
Aggeletopoulou, I., Thomopoulos, K., Mouzaki, Α., & Triantos, C. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158465 · Cited by 57
Serology in autoimmune hepatitis: A clinical-practice approach
Beretta‐Piccoli, B. T., Mieli‐Vergani, G., & Vergani, D. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.10.006 · Cited by 63
Harms, M. H., Janssen, Q. P., Adam, R. A., Duvoux, C., Mirza, D. F., Hidalgo, E. L., Watson, C. J. E., Wigmore, S. J., Pinzani, M., Isoniemi, H., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15060 · Cited by 55
The Pathophysiology of Cholestasis and Its Relevance to Clinical Practice
Onofrio, F. Q., & Hirschfield, G. M. (2020) · Clinical Liver Disease · doi:10.1002/cld.894 · Cited by 56
Self-citationTreatment of Dyslipidemia in Common Liver Diseases
Speliotes, E. K., Balakrishnan, M., Friedman, L. S., & Corey, K. E. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.023 · Cited by 56
Sex-related factors in autoimmune liver diseases
Schwinge, D., & Schramm, C. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0715-8 · Cited by 58
Self-citationJin, C., Jiang, P., Zhang, Z., Han, Y., Wen, X., Zheng, L., Kuang, W., Lian, J., Yu, G., Qian, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53104-9 · Cited by 56
Robles‐Díaz, M., Nežić, L., Vujić‐Aleksić, V., & Bjornsson, E. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.744488 · Cited by 56
“Ursodeoxycholic acid (UDCA) is recommended by liver societies for the treatment of patients with primary biliary cholangitis (PBC) (Hirschfield et al., 2017; Hirschfield et al., 2018; Lindor et al., 2019).”
BackgroundInfluentialTreatment of Pruritus Secondary to Liver Disease
Düll, M. M., & Kremer, A. E. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0713-6 · Cited by 53
Cortez‐Pinto, H., Liberal, R., Lopes, S., Machado, M. V., Carvalho, J., Dias, T., Santos, A., Agostinho, C., Figueiredo, P., Loureiro, R. V., et al. (2021) · United European Gastroenterology Journal · doi:10.1002/ueg2.12095 · Cited by 53
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
Yokoda, R. T., & Carey, E. J. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000268 · Cited by 52
Gazda, J., Dražilová, S., Janíčko, M., & Jarčuška, P. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/9151525 · Cited by 60
“Ursodeoxycholic acid is the firstline treatment and is well accessible in the European Union [1].”
BackgroundInfluentialDetection of antinuclear antibodies: recommendations from EFLM, EASI and ICAP
Bonroy, C., Vercammen, M. J., Fierz, W., Andrade, L. E. C., Hoovels, L. V., Infantino, M. G., Fritzler, M. J., Bogdanos, D. P., Kozmar, A., Nespola, B., et al. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0209 · Cited by 54
Slooter, C. D., van den Brand, F. F., Lleò, A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000589 · Cited by 52
Binda, C., Gibiino, G., Coluccio, C., Sbrancia, M., Dajti, E., Sinagra, E., Capurso, G., Sambri, V., Cucchetti, A., Ercolani, G., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10020312 · Cited by 52
“Primary biliary cholangitis (PBC) is an uncommon chronic inflammatory autoimmune cholestatic liver disease that can have a serious course and progress to end-stage liver disease when untreated [84].”
BackgroundAntibodies to gp210 and understanding risk in patients with primary biliary cholangitis
Haldar, D., Janmohamed, A., Plant, T. D., Davidson, M., Norman, H., Russell, E. A., Serevina, O., Chung, K., Qamar, K., Gunson, B. K., et al. (2020) · Liver International · doi:10.1111/liv.14688 · Cited by 53
Self-citationNevens, F., Trauner, M., & Manns, M. P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.007 · Cited by 51
NLRP3 Inflammasome in Acute and Chronic Liver Diseases
Sayaf, K., Battistella, S., & Russo, F. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084537 · Cited by 55
“If patients do not respond to these initial treatments, potential alternatives include oral opiate antagonists and selective serotonin reuptake inhibitors (SSRIs) [81].”
BackgroundPrimary biliary cholangitis: pathogenic mechanisms
Prìeto, J., Bañales, J. M., & Medina, J. F. (2020) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000703 · Cited by 48
Schramm, C., Wedemeyer, H. H., Mason, A. L., Hirschfield, G. M., Levy, C., Kowdley, K. V., Milkiewicz, P., Janczewska, E., Malova, E. S., Sanni, J., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100544 · Cited by 58
Self-citationNayagam, J. S., Williamson, C., Joshi, D., & Thompson, R. J. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16118 · Cited by 53
PDIA3 epitope-driven immune autoreactivity contributes to hepatic damage in type 2 diabetes
Clement, C. C., Osan, J. K., Buqué, A., Nanaware, P. P., Chang, Y., Perino, G., Shetty, M., Yamazaki, T., Tsai, W. L., Urbanska, A. M., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abl3795 · Cited by 49
de Graaf, K., Lapeyre, G., Guilhot, F., Ferlin, W. G., Curbishley, S. M., Carbone, M., Richardson, P., Moreea, S., McCune, C. A., Ryder, S. D., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1170 · Cited by 48
Self-citationEfe, C., Taşçılar, K., Henriksson, I., Lytvyak, E., Alalkim, F., Trivedi, H. D., Eren, F., Eliasson, J., Beretta‐Piccoli, B. T., Fischer, J., et al. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000290 · Cited by 48
NLRP3 inflammasome activation mechanism and its role in autoimmune liver disease
Guan, Y., Gu, Y., Li, H., Liang, B., Han, C., Zhang, Y., Liu, Q., Wei, W., & Ma, Y. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022137 · Cited by 48
“Without timely treatment, PBC will eventually develop into advanced biliary cirrhosis [107].”
BackgroundHa, Y., Jeong, I., & Kim, T. H. (2022) · Biomedicines · doi:10.3390/biomedicines10102530 · Cited by 47
Bile Acids in Cholestasis and its Treatment
Arab, J. P., Cabrera, D., & Arrese, M. A. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0010.5497 · Cited by 49
Carino, A., Biagioli, M., Marchianò, S., Fiorucci, C., Bordoni, M., Roselli, R., Giorgio, C. D., Baldoni, M., Ricci, P., Monti, M. C., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158733 · Cited by 48
Kajio, N., Takeshita, M., Suzuki, K., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218881 · Cited by 47
Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis
Gatselis, N., Goet, J. C., Zachou, K., Lammers, W. J., Janssen, H. L. A., Hirschfield, G. M., Corpechot, C., Lindor, K. D., Invernizzi, P., Mayo, M. J., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.08.013 · Cited by 46
Self-citationIgG4-related cholangitis – a mimicker of fibrosing and malignant cholangiopathies
Kersten, R., Trampert, D. C., Herta, T., Hubers, L. M., Wenniger, L. J. M. D. B., Verheij, J., van de Graaf, S. F. J., & Beuers, U. H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.005 · Cited by 52
Self-citationHarms, M. H., de Veer, R. C., Lammers, W. J., Corpechot, C., Thorburn, D., Janssen, H. L. A., Lindor, K. D., Trivedi, P. J., Hirschfield, G. M., Parés, A. R., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-319057 · Cited by 52
Self-citationThe Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases
Cargill, T., & Culver, E. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661196 · Cited by 46
Farnesoid X Receptor Agonists: A Promising Therapeutic Strategy for Gastrointestinal Diseases
Almeqdadi, M., & Gordon, F. D. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.013 · Cited by 47
Epidemiology of primary biliary cholangitis in Italy: Evidence from a real-world database
Marzioni, M., Bassanelli, C., Ripellino, C., Urbinati, D., & Alvaro, D. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.11.008 · Cited by 45
Self-citationJohn, B. V., Khakoo, N. S., Schwartz, K. B., Aitchenson, G., Levy, C., Dahman, B. A., Deng, Y., Goldberg, D. S., Martin, P. B., Kaplan, D. E., et al. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001280 · Cited by 47
Contemporary epidemiology of primary biliary cholangitis
Colapietro, F., Bertazzoni, A., & Lleo, A. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.001 · Cited by 43
The history and future of bile acid therapies
Beuers, U. H., Bañales, J. M., Karpen, S. J., Keitel, V., Williamson, C., & Trauner, M. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.06.010 · Cited by 45
Self-citationSymptoms of PBC – Pathophysiology and management
Khanna, A., Leighton, J., Wong, L. L., & Jones, D. E. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.007 · Cited by 44
Self-citationManagement of primary sclerosing cholangitis and its complications: an algorithmic approach
Prokopič, M., & Beuers, U. H. (2020) · Hepatology International · doi:10.1007/s12072-020-10118-x · Cited by 47
Self-citationTh17 cell frequency is associated with low bone mass in primary sclerosing cholangitis
Schmidt, T., Schwinge, D., Rolvien, T., Jeschke, A., Schmidt, C., Neven, M., Butscheidt, S., Kriz, M., Kunzmann, L., Mussawy, H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.035 · Cited by 42
Self-citationDiagnostic Approach to Abnormal Alkaline Phosphatase Value
Minisola, S., Cipriani, C., Colangelo, L., Labbadia, G., Pepe, J., & Magnusson, P. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.11.019 · Cited by 52
Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review
Beretta‐Piccoli, B. T., Invernizzi, P., Gershwin, M. E., & Mainetti, C. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8649-9 · Cited by 42
Self-citationSerum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis
Joshita, S., Umemura, T., Usami, Y., Yamashita, Y., Norman, G. L., Sugiura, A., Yamazaki, T., Fujimori, N., Kimura, T., Matsumoto, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26531-0 · Cited by 45
Hegade, V. S., Pechlivanis, A., McDonald, J. A. K., Rees, D., Corrigan, M., Hirschfield, G. M., Taylor-Robinson, S. D., Holmes, E. C., Marchesi, J. R., Kendrick, S. F. W., et al. (2019) · Liver International · doi:10.1111/liv.14069 · Cited by 42
Self-citationLiver infiltrating T cells regulate bile acid metabolism in experimental cholangitis
Glaser, F., John, C., Engel, B., Hoeh, B., Weidemann, S. A., Dieckhoff, J., Stein, S., Becker, N., Casar, C., Schuran, F. A., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.030 · Cited by 41
Self-citationA Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.
Onofrio, F. Q., Hirschfield, G. M., & Gulamhusein, A. F. (2019) · Europe PMC (PubMed Central) · Cited by 42
Self-citationGomez, E., Garcia Buey, L., Molina, E., Casado, M., Conde, I., Berenguer, M., Jorquera, F., Simón, M., Olveira, A., Hernández‐Guerra, M., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16181 · Cited by 41
Obeticholic Acid for Primary Biliary Cholangitis
Floreani, A., Gabbia, D., & De Martin, S. (2022) · Biomedicines · doi:10.3390/biomedicines10102464 · Cited by 41
Han, W., Huang, C., Zhang, Q., Tao, S., Hu, X., Xu, J., Jiang, R., Xu, B., Liu, Y., & Hou, J. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13714 · Cited by 40
Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders
Molinaro, A., & Marschall, H. (2022) · Biochemical Society Transactions · doi:10.1042/bst20210658 · Cited by 44
Evaluation and Management of Pruritus in Primary Biliary Cholangitis
Düll, M. M., & Kremer, A. E. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.009 · Cited by 41
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis
Lam, L., Soret, P., Lemoinne, S., Hansen, B. E., Hirschfield, G. M., Gulamhusein, A. F., Montaño‐Loza, A. J., Lytvyak, E., Parés, A. R., Olivas, I., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.06.035 · Cited by 44
Self-citationTurco, M., Cazzagon, N., Franceschet, I., Formentin, C., Frighetto, G., Giordani, F., Cellini, N., Mazzotta, G. M., Costa, R., Middleton, B., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01530 · Cited by 39
Lysophosphatidic acid activates satellite glia cells and Schwann cells
Robering, J. W., Gebhardt, L., Wolf, K., Kühn, H., Kremer, A. E., & Fischer, M. J. M. (2019) · Glia · doi:10.1002/glia.23585 · Cited by 42
Gaspar, R., Rodrigues, S. G., Silva, M., Costa‐Moreira, P., Morais, R., Andrade, P., Cardoso, H., Albuquerque, A., Liberal, R., & Macedo, G. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.03.016 · Cited by 41
Wunsch, E., Raszeja‐Wyszomirska, J., Barbier, O., et al. (2018) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld.2014.1121.273.icz · Cited by 40
Sharma, C., Cococcia, S., Ellis, N., Parkes, J., & Rosenberg, W. M. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15482 · Cited by 44
Ursodeoxycholic acid in pregnancy?
de Vries, E., & Beuers, U. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.020 · Cited by 40
Self-citationNewer Approaches to the Management of Pruritus in Cholestatic Liver Disease
Düll, M. M., & Kremer, A. E. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00517-x · Cited by 42
Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review
Rinaldi, L., Giorgione, C., Mormone, A., Esposito, F., Rinaldi, M., Berretta, M., Marfella, R., & Romano, C. P. (2023) · Viruses · doi:10.3390/v15081730 · Cited by 44
Overlap Syndrome of Autoimmune Hepatitis and Primary Biliary Cholangitis
To, U. K., & Silveira, M. G. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.010 · Cited by 42
Clinical Management of Primary Biliary Cholangitis—Strategies and Evolving Trends
Gao, L., Wang, L., Woo, E., He, X., Yang, G., Bowlus, C., Leung, P. S. C., & Gershwin, M. E. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08772-7 · Cited by 39
Engel, B., Taubert, R., Jaeckel, E., & Manns, M. P. (2020) · Liver International · doi:10.1111/liv.14378 · Cited by 42
Coukos, A., Vionnet, J., Obéid, M., Bouchaab, H., Peters, S., Latifyan, S., Wicky, A. M., Michielin, O. A., Chtioui, H., Moradpour, D., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005635 · Cited by 43
Murillo Perez, C. F., Ioannou, S., Hassanally, I., Trivedi, P. J., Corpechot, C., van der Meer, A. J., Lammers, W. J., Battezzati, P. M., Lindor, K. D., Nevens, F., et al. (2023) · Liver International · doi:10.1111/liv.15592 · Cited by 39
Self-citationPrimary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
Jones, D. E. J., Beuers, U., Bonder, A., Carbone, M., Culver, E., Dyson, J., Gish, R. G., Hansen, B. E., Hirschfield, G., Jones, R., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000864 · Cited by 38
Self-citationPrimary Biliary Cholangitis: advances in management and treatment of the disease
Invernizzi, P., Floreani, A., Carbone, M., Marzioni, M., Craxı̀, A., Muratori, L., Gentilucci, U. V., Gardini, I., Gasbarrini, A., Kruger, P., et al. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.05.001 · Cited by 39
Self-citationGenetic determinants of cholangiopathies: Molecular and systems genetics
Reichert, M., Hall, R. A., Krawczyk, M. J., & Lammert, F. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.07.029 · Cited by 40
Webb, G. J., Rahman, S. R., Levy, C., & Hirschfield, G. M. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14579 · Cited by 39
Self-citationManagement of Chronic Hepatic Itch
Düll, M. M., & Kremer, A. E. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.008 · Cited by 35
Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy
Wah‐Suárez, M., Danford, C. J., Patwardhan, V. R., Jiang, Z. G., & Bonder, A. (2019) · Frontline Gastroenterology · doi:10.1136/flgastro-2018-101124 · Cited by 42
Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis
Joshita, S., Umemura, T., Yamashita, Y., Sugiura, A., Yamazaki, T., Fujimori, N., Matsumoto, A., & Tanaka, E. (2019) · Hepatology Research · doi:10.1111/hepr.13361 · Cited by 38
Diagnosis and treatment of primary biliary cholangitis
Laschtowitz, A., de Veer, R. C., der Meer, A. J. V., & Schramm, C. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620919585 · Cited by 38
“Still, as for the few patients without PBC-specific autoantibodies, liver biopsy remains essential for those in whom coexistence of AIH or non-alcoholic steatohepatitis is suspected.(1,2)”
BackgroundMethodInfluentialSelf-citationMontaño‐Loza, A. J., & Corpechot, C. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.062 · Cited by 41
Self-citationReview article: pathophysiology and management of primary biliary cholangitis
Leung, K. K., Deeb, M., & Hirschfield, G. M. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16023 · Cited by 39
Self-citation
Metadata
- Authors
- Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C.
- Affiliations
- European Association for the Study of the Liver (CH)
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 67
- Issue
- 1
- Pages
- 145-172
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2605729742
- Semantic Scholar
- a6a2b9566f65a4e01153b95ecdcd0d4106d9fed9
- Cited by
- 1,480
- References
- 274
- Citations by year
- 2026: 166 · 2025: 207 · 2024: 205 · 2023: 178 · 2022: 175 · 2021: 140 · 2020: 136 · 2019: 131 · 2018: 111 · 2017: 30
- FWCI
- 68.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- European Association for the Study of the Liver
- DFG
- Helmut and Hannelore Greve Foundation
- YAEL-Foundation
- NIHR
- Birmingham Liver Biomedical Research Centre
- EU Marie Curie scheme
- Newcastle Biomedical Research Centre
- Medical Research Council
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, autoimmune cholestatic liver disease, antimitochondrial antibodies, cholestatic hepatitis, risk stratification, ursodeoxycholic acid, obeticholic acid, fibrates, budesonide, off-label therapy, individualized care, diagnosis, management
- MeSH terms
- Cholangitis, Female, Humans, Male, Prognosis, Ursodeoxycholic Acid, Liver Transplantation, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-26 (prompt extract-v2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
